Literature DB >> 24213097

Lymph node metastasis in patients with epithelial ovarian cancer macroscopically confined to the ovary: review of a single-institution experience.

Volkan Ulker1, Oguzhan Kuru, Ceyhun Numanoglu, Ozgur Akbayır, Ibrahim Polat, Mehmet Uhri.   

Abstract

BACKGROUND: To evaluate the patterns of lymphatic spread in epithelial ovarian cancer (EOC) macroscopically confined to the ovary and to determine risk factors for lymph node metastasis.
MATERIALS AND METHODS: All patients with clinically apparent stage IA/B/C EOCs who underwent staging surgery between January 2003 and February 2013 were retrospectively identified.
RESULTS: Two hundred and thirty-six (n = 236) consecutive patients were operated for primary epithelial ovarian carcinoma. Sixty-two of these patients (26.2 %) who underwent a comprehensive staging procedure including pelvic and paraaortic lymphadenectomy were diagnosed with tumors confined to one or two ovaries (stage IA/B/C). Of these 62 patients, 17 (27.4 %) had upstaged disease and 8 (12.9 %) had lymph node metastasis. Tumor histology was serous in 25 patients (40.3 %), mucinous in 23 patients (37 %), endometrioid in 9 patients (14.5 %), and clear cell in 5 patients (8 %). Positive lymph node status was found in 20 % (5/25) of those with serous histology while this rate was only 8.1 % (3/37) in those with non-serous disease. Although the presence of ascites was not associated with an increased risk of lymph node involvement (p = 0.24), positive peritoneal cytology (p = 0.001) and grade 3 disease (p = 0.001) were significant predictors of lymph node involvement.
CONCLUSION: All patients diagnosed with EOC macroscopically confined to the ovary should be considered for comprehensive staging surgery including pelvic and paraaortic lymphadenectomy.

Entities:  

Mesh:

Year:  2013        PMID: 24213097     DOI: 10.1007/s00404-013-3078-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

2.  Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.

Authors:  Jennifer J Mueller; Marie Holzapfel; Chan H Han; Kevin Santos; Camille Gunderson; Kathleen Moore; Britt Erickson; Charles A Leath; Elena Diaz; Christine Walsh; Stephanie L Wethington; Sheila Z Dejbakhsh; Richard R Barakat; Ginger J Gardner; David M Hyman; Robert A Soslow; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

Review 3.  Normal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases - A Case Report and Literature Review.

Authors:  Nicolae Bacalbasa; Irina Balescu; Cristian Balalau; Olivia Ionescu; Claudia Stoica
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

4.  Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment.

Authors:  Cornelia Bachmann; Robert Bachmann; Falko Fend; Diethelm Wallwiener
Journal:  J Cancer       Date:  2016-11-09       Impact factor: 4.207

5.  Survival effect of different lymph node staging methods on ovarian cancer: An analysis of 10 878 patients.

Authors:  Jieyu Wang; Jun Li; Ruifang Chen; Xin Lu
Journal:  Cancer Med       Date:  2018-08-18       Impact factor: 4.452

6.  MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling.

Authors:  Ying Fang; Changyan Xu; Yan Fu
Journal:  J Biol Res (Thessalon)       Date:  2015-10-22       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.